.jetcityimage/iStock Editorial through Getty Images Morgan Stanley has opted for Eli Lilly (NYSE: LLY) as its leading biopharma pick for 2025 and also ranked one more 9 names in the area as over weight. The expenditure banking company pointed out in a note that it continues to think “diabesity is set to come to be.